CAR-T therapies like Novartiss Kymriah (tisagenlecleucel) and Gilead/Kites Yescarta (axicabtagene ciloleucel), lentiviral gene therapies like bluebird bios betibeglogene/Zynteglo, adeno-associated virus (AAV)-based programs like Sareptas Elevidys (delandistrogene moxeparvovec) and CSL Behrings Hemgenix (etranacogene dezaparvovec), and gene editing programs using CRISPR/Cas9 or base editing technologies, all involve manufacturing processes of extraordinary complexity that cannot be adequately protected by conventional composition-of-matter patents alone

Solutions: Use a higher concentration with smaller reconstitution volume, which does not actually solve the stability issue since the same amount of time passes Start at a higher dose point if your protocol allows (only if you have already titrated up with a smaller vial) Consider aliquoting into smaller sterile vials and freezing portions for later use (reduces contamination risk to the main vial) Share the reconstitution timing with your dosing schedule, only reconstituting when you are at a dose where you will use the vial within 28-60 days For researchers at 10 mg or 15 mg weekly, the 60 mg vial is perfect
It may even illuminate some of the mysteries around how appetite works in the first place
Male sexual desire: an overview of biological, psychological, sexual, relational, and cultural factors influencing desire
Global revenue from Tremfya was $2.67 billion in 2022, a 25.43 percent increase from $2.13 billion in 2021
In humans, OCT1 is mainly expressed in the sinusoid membrane of hepatocytes, whereas in rodents, OCT1 is strongly expressed in the basolateral membrane of renal proximal tubule cells